Teva schedules third-quarter results for November 3: Teva stock sits 2.02 percent below its high
Published on 10/13/2026 at 14:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS- Teva has scheduled its third-quarter 2026 results for November 3, 2026, with the release planned before the conference call.
- Teva stock carried a USD 47.9 billion market capitalization and a USD 18.83 to USD 42.02 52-week range on October 12, 2026.
- Teva stock last traded at USD 41.17 on October 12, 2026, up 0.17 percent from USD 41.10.
- The stock traded at 68.39 times earnings and offered no reported trailing dividend yield in the October 12 quote.
Teva Pharmaceutical Industries Limited (US8816242098) has scheduled its third-quarter 2026 results for November 3, 2026, with the release planned for 7:00 a.m. ET and a conference call at 8:00 a.m. ET, according to Teva on September 23, 2026. The company is listed on the NYSE and TASE under TEVA. Its stock last traded at USD 41.17 on October 12, 2026 at 4:00 p.m. ET, up 0.17 percent from USD 41.10.
Market value reaches USD 47.9 billion
Teva had a market capitalization of USD 47.9 billion on October 12, 2026. The quote stood inside a USD 18.83 to USD 42.02 52-week range, leaving the price 2.02 percent below the high and 118.59 percent above the low.
The range places the stock near its yearly peak while preserving a wide gap to the low. That contrast matters because the current valuation reflects a much stronger market level than the lower end of the past year, while the earnings multiple remains elevated relative to larger established drugmakers.
Valuation stays above peer levels
Teva traded at a price-to-earnings ratio of 68.39 on October 12, 2026. The quote carried no reported trailing dividend yield, so the scheduled November results remain the next dated company event for the market.
Comparison with peers
Teva (NYSE, USD): plus 0.17 percent, P/E 68.39, market capitalization USD 47.9 billion
Bristol-Myers Squibb (NYSE, USD): minus 2.60 percent, P/E 12.68, market capitalization USD 117.6 billion
Vertex Pharmaceuticals (NASDAQ, USD): minus 0.60 percent, P/E 29.51, market capitalization USD 128.7 billion
Price remains below the yearly high
Teva last traded at USD 41.17 on October 12, 2026 at 4:00 p.m. ET, 0.17 percent above USD 41.10 and 2.02 percent below the 52-week high of USD 42.02. The November 3, 2026 results date gives investors the next fixed point for assessing revenue, earnings and management commentary.
Teva stock market data
- Company: Teva Pharmaceutical Industries Limited
- ISIN: US8816242098
- Ticker: TEVA
- Primary exchange: NYSE and TASE
- Price as of October 12, 2026 at 4:00 p.m. ET: USD 41.17
- Change versus prior close: plus 0.17 percent
- Market capitalization: USD 47.9 billion (as of October 12, 2026)
- 52-week range: USD 18.83-USD 42.02 (as of October 12, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
